Cancer diagnostics

Uniogen’s product portfolio includes unique glycovariant immunoassays for the early and timely diagnostics of cancer. Our assay technology is based on nanoparticles coated with glycan binders at a high density, which translates to an improved sensitivity and specificity compared to conventional biomarker assays. The functional binding affinity of a coated nanoparticle is superior to individual binders due to the high number of binder molecules on an individual particle. 

Uniogen’s first proprietary test for the early detection of ovarian cancer is currently under development. Although ovarian cancer is a common malignancy with a relatively high mortality, no clinical screening method or early-stage diagnostic tool has been available up to date. In addition, we have patents for testing of other cancer types, such as pancreatic, breast and intestinal cancers.

Ovarian Cancer Assay Kit with components

Ovarian cancer diagnostics – Early detection saves lives

Current tools for ovarian cancer diagnosis are not sensitive or accurate enough, making clinicians dependent on invasive procedures such as laparoscopy. Therefore, the development of better blood-based diagnostic tests is of importance. Uniogen’s glycovariant assay has multiple benefits as compared with the broadly used CA125 biomarker:

  • Improved specificity due to detection of cancer specific glycan structures
  • Superior sensitivity through particle- based labels
  • Initial clinical validity confirmed
  • Strong IP protection

Uniogen is committed to providing an innovative solution for early ovarian cancer diagnostics that empower patients and healthcare providers to act sooner.

There is an unmet need for creation of diagnostic tools, which can identify ovarian cancer at its earliest and most treatable stages. Ovarian cancer is often diagnosed at an advanced stage due to the lack of effective early detection methods, significantly reducing the chances of successful treatment. We have seen firsthand the impact that the late-stage diagnosis can have on patients and their families. We are hopeful that Uniogen’s innovative approach will help change this narrative for the better.

Taru Salovaara
President
Gynaecological Cancer patients in Finland

Eva-Maria Strömsholm
Vice-President
Gynaecological Cancer patients in Finland

Abacus Diagnostica, Kaivogen and Labrox are now Uniogen

Uniogen is a global pioneer in clinical diagnostics, point-of-care testing, and instrumentation for life sciences.

Uniogen – Enabling diagnosis and care at first appointment